NASDAQ$PRVA
Privia Health Group, Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Privia Health's financial performance increased in Q2 2022, marked by substantial growth in practice collections and implemented providers.
Privia Health reported strong growth in Q2 2022, with a significant increase in practice collections, implemented providers, and value-based care attributed lives. The company's revenue and adjusted EBITDA also saw substantial growth compared to the prior year. Privia Health repaid all outstanding debt in the quarter.
- Total revenue increased by 48.6% compared to Q2 2021.
- Practice collections grew by 67.6% compared to Q2 2021.
- Implemented providers increased by 31.5% compared to Q2 2021.
- Value-based care attributed lives increased by 15.8% compared to Q2 2021.
Headline financials
Revenue & EPS history
Privia Health · Revenue · Quarterly
$336M
Revenue by segment
Privia Health · $417M total across 6 segments · Q3 2023
- FFS-patient care$246M—58.8%
- Capitated revenue$88.5M—21.2%
- Shared savings$33.5M—8.0%
- FFS-administrative services$29.8M—7.2%
- Care management fees (PMPM)$17.8M—4.3%
- Other revenue$2.03M—0.5%
Forward guidance
Privia Health updated its full-year 2022 guidance.
Tailwinds
- Implemented Providers: Mid-to-High End of the unchanged range (3,625 - 3,725)
- Attributed Lives: Midpoint of the unchanged range (860,000 - 890,000)
- Practice Collections: Mid-to-High End of the range ($2,050M - $2,200M)
- GAAP Revenue: High End of the range ($1,225M - $1,300M)
- Care Margin: High End of the range ($280M - $295M)
Headwinds
- Platform Contribution: $137M - $142M
- Adjusted EBITDA: $57M - $60M
- 2022 guidance includes only previously announced new market entries.
- Capital expenditures expected to be less than $1 million in full-year 2022.
- Management has not reconciled forward-looking non-GAAP measures to their most directly comparable GAAP measures of operating income and net income.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+3.5%
Avg return
Earnings day
+4.1%
Avg return
5 days after
+1.3%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+28.3%
Q1 2022
Best reaction
-8.8%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | -4.1% | -9.9% | |
| Q4 2025 | +9.9% | +4.9% | -11.6% | |
| Q3 2025 | -4.3% | -2.8% | -4.7% | |
| Q1 2025 | +7.3% | +4.2% | -0.6% | |
| Q4 2024 | +5.8% | +6.1% | -6.1% | |
| Q3 2024 | +0.7% | +6.7% | +0.1% | |
| Q2 2024 | +4.4% | +9.7% | +2.1% | |
| Q1 2024 | -4.7% | -4.3% | -9.1% | |
| Q4 2023 | +9.4% | +11.6% | -2.0% | |
| Q3 2023 | +9.7% | +9.0% | +6.0% | |
| Q2 2023 | +1.6% | -1.2% | -2.3% | |
| Q1 2023 | +7.3% | +7.2% | -8.3% | |
| Q4 2022 | +4.6% | +6.3% | +1.7% | |
| Q3 2022 | +5.3% | +6.2% | -9.7% | |
| Q2 2022 | +0.6% | -4.6% | +13.3% | |
| Q1 2022 | +28.3% | +25.1% | +41.0% | |
| Q4 2019 | -2.0% | +6.4% | -3.5% | |
| Q4 2021 | +3.3% | +7.5% | +10.4% | |
| Q3 2020 | +12.3% | +18.3% | -14.5% | |
| Q3 2021 | +12.3% | +18.3% | -14.5% | |
| Q2 2020 | -8.8% | -14.8% | -26.5% | |
| Q2 2021 | -8.8% | -14.8% | -26.5% | |
| Q4 2020 | -2.2% | +0.7% | +34.8% | |
| Q1 2020 | -2.2% | +0.7% | +34.8% | |
| Q1 2021 | -1.1% | +0.9% | +39.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro